Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.8M Hold
14,363
0.07% 123
2026
Q1
$3.22M Sell
14,363
-1,226
-8% -$306K 0.09% 110
2025
Q4
$3.75M Buy
15,589
+108
+0.7% +$27.6K 0.09% 96
2025
Q3
$4.24M Sell
15,481
-2,541
-14% -$694K 0.1% 92
2025
Q2
$4.65M Sell
18,022
-40
-0.2% -$9.54K 0.11% 89
2025
Q1
$4.04M Sell
18,062
-189
-1% -$44.1K 0.11% 92
2024
Q4
$4.17M Buy
18,251
+3,551
+24% +$855K 0.11% 90
2024
Q3
$3.59M Hold
14,700
0.1% 96
2024
Q2
$2.81M Buy
14,700
+12,500
+568% +$2.54M 0.08% 104
2024
Q1
$436K Buy
+2,200
New +$403K 0.01% 229

Other funds holding RMD

Chicago Capital's RMD Position: Q2 2026 in Review

Chicago Capital held its ResMed (RMD) position steady in Q2 2026 at 14,363 shares worth $2.8M. The position accounts for 0.07% of the portfolio, ranked #123.

Chicago Capital first reported a position in RMD in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.65M in Q2 2025. 319 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Chicago Capital held 14,363 shares of ResMed worth $2.8M as of Q2 2026.
  • Chicago Capital left its ResMed share count unchanged in Q2 2026.
  • ResMed made up 0.07% of Chicago Capital's portfolio in Q2 2026, its #123 holding.
  • Chicago Capital first reported a position in ResMed in Q1 2024 and has held it in 10 quarters since.
  • Chicago Capital's ResMed position peaked at $4.65M in Q2 2025.
  • 319 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Chicago Capital's 13F filing for Q2 2026, filed 28 Jul 2026.